Involvement of SYCP2L and TDRD3 gene variants on ovarian reserve and reproductive outcomes: a cross-sectional study
- PMID: 37417852
- PMCID: PMC10712833
- DOI: 10.5935/1518-0557.20220074
Involvement of SYCP2L and TDRD3 gene variants on ovarian reserve and reproductive outcomes: a cross-sectional study
Abstract
Objective: Single nucleotide variants have been implicated in the response to fertility treatment and a pharmacogenomic approach may help to customize therapy based on patient genome. We aimed to evaluate the effect, individual and combined, of SYCP2L (rs2153157:G>A) and TDRD3 (rs4886238:G>A) variants on ovarian reserve, response to controlled ovarian stimulation (COS) and reproductive outcomes of women undergoing in vitro fertilization (IVF) treatment.
Methods: This cross-sectional study included 149 normoovulatory women undergoing IVF. Genotyping was performed using the TaqMan real-time polymerase chain reaction method. Clinical parameters and reproductive outcomes were compared according to the genotypes of the variants studied.
Results: Considering ovarian reserve, there were no significant differences among SYCP2L or TDRD3 genotypes in terms of FSH levels or AFC; however, AMH levels were significantly different in carriers of both variants. Regarding the SYCP2L rs2153157:G>A variant, lower AMH levels were observed in women carrying an AA genotype compared to women carrying a heterozygous genotype (p=0.01). Considering the TDRD3 rs4886238:G>A variant, women carrying an AA genotype presented higher AMH levels than carriers of GG and GA genotypes (p=0.025). Nevertheless, no difference was found regarding response to COS or reproductive outcomes. Considering the combined effect of the variants, women carrying the heterozygous genotype of both variants presented statistically increased AMH levels compared to SYCP2L rs2153157 AA genotype carriers and TDRD3 rs4886238 GG genotype carriers (p=0.042).
Conclusions: Individually and combined, the SYCP2L rs2153157 and TDRD3 rs4886238 variants have an effect on AMH level.
Keywords: in vitro fertilization; infertility; ovarian reserve; pharmacogenetic; single nucleotide variant.
Similar articles
-
Genetic variants associated with female reproductive ageing--potential markers for assessing ovarian function and ovarian stimulation outcome.Reprod Biomed Online. 2015 Aug;31(2):199-209. doi: 10.1016/j.rbmo.2015.05.001. Epub 2015 May 14. Reprod Biomed Online. 2015. PMID: 26099445
-
A single nucleotide polymorphism of bone morphogenic protein-15 is not associated with ovarian reserve or response to ovarian stimulation.Hum Reprod. 2014 Dec;29(12):2832-7. doi: 10.1093/humrep/deu264. Epub 2014 Oct 21. Hum Reprod. 2014. PMID: 25336710
-
Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients.Front Endocrinol (Lausanne). 2021 Aug 30;12:702061. doi: 10.3389/fendo.2021.702061. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34526967 Free PMC article.
-
Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications.Hum Reprod Update. 2014 Sep-Oct;20(5):688-701. doi: 10.1093/humupd/dmu020. Epub 2014 May 12. Hum Reprod Update. 2014. PMID: 24821925 Review.
-
Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers.Minerva Ginecol. 2017 Jun;69(3):250-258. doi: 10.23736/S0026-4784.17.04044-8. Epub 2017 Mar 7. Minerva Ginecol. 2017. PMID: 28271699 Review.
References
-
- Alviggi C, Conforti A, Caprio F, Gizzo S, Noventa M, Strina I, Pagano T, De Rosa P, Carbone F, Colacurci N, De Placido G. In Estimated Good Prognosis Patients Could Unexpected “Hyporesponse” to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor? Reprod Sci. 2016;23:1103–1108. doi: 10.1177/1933719116630419. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases